$8.90
0.65[7.88%]
At close: Apr 18
$8.90
0[0.00%]
PreMarket: 9:01AM EDT
Oncternal Therapeutics
(NASDAQ:ONCT)Oncternal Therapeutics Stock (NASDAQ:ONCT), Analyst Ratings, Price Targets, Predictions
Oncternal Therapeutics Inc has a consensus price target of $6.05, established from looking at the 18 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 15, 2024, January 29, 2024, and December 27, 2023. With an average price target of $20 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 124.72% upside for Oncternal Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Brookline Capital
Cantor Fitzgerald
Maxim Group
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Oncternal Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/15/2024 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | 214.61% | HC Wainwright & Co. | Raghuram Selvaraju | $30 → $28 | Maintains | Buy | Get Alert |
| 01/29/2024 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | 237.08% | HC Wainwright & Co. | Raghuram Selvaraju | $2 → $30 | Maintains | Buy | Get Alert |
| 12/27/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -77.53% | HC Wainwright & Co. | Raghuram Selvaraju | → $40 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -77.53% | Brookline Capital | Kemp Dolliver | → $40 | Upgrade | Hold → Buy | Get Alert |
| 09/18/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -77.53% | HC Wainwright & Co. | Raghuram Selvaraju | → $40 | Upgrade | Neutral → Buy | Get Alert |
| 09/07/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -85.39% | Cantor Fitzgerald | Li Watsek | → $26 | Reiterates | Neutral → Neutral | Get Alert |
| 06/06/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
| 04/04/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | — | Maxim Group | Naureen Quibria | — | Downgrade | Buy → Hold | Get Alert |
| 04/04/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | — | Brookline Capital | Kemp Dolliver | — | Downgrade | Buy → Hold | Get Alert |
| 04/04/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -85.39% | Cantor Fitzgerald | Li Watsek | $80 → $26 | Maintains | Overweight | Get Alert |
| 04/04/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 04/04/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | — | Oppenheimer | Hartaj Singh | — | Downgrade | Outperform → Perform | Get Alert |
| 03/22/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | 1.12% | Oppenheimer | Hartaj Singh | $280 → $180 | Maintains | Outperform | Get Alert |
| 03/14/2023 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -21.35% | HC Wainwright & Co. | Raghuram Selvaraju | → $140 | Reiterates | → Buy | Get Alert |
| 12/22/2022 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -55.06% | Cantor Fitzgerald | Li Watsek | → $80 | Initiates | → Overweight | Get Alert |
| 08/10/2022 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -21.35% | HC Wainwright & Co. | Raghuram Selvaraju | $160 → $140 | Maintains | Buy | Get Alert |
| 05/10/2022 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -60.67% | Maxim Group | Naureen Quibria | → $70 | Initiates | → Buy | Get Alert |
| 02/24/2022 | ONCT | Buy Now | Oncternal Therapeutics | $8.90 | -43.82% | BTIG | Kaveri Pohlman | → $100 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Oncternal Therapeutics (ONCT)?
The latest price target for Oncternal Therapeutics (NASDAQ: ONCT) was reported by HC Wainwright & Co. on April 15, 2024. The analyst firm set a price target for $28.00 expecting ONCT to rise to within 12 months (a possible 214.61% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oncternal Therapeutics (ONCT)?
The latest analyst rating for Oncternal Therapeutics (NASDAQ: ONCT) was provided by HC Wainwright & Co., and Oncternal Therapeutics maintained their buy rating.
When was the last upgrade for Oncternal Therapeutics (ONCT)?
The last upgrade for Oncternal Therapeutics Inc happened on December 4, 2023 when Brookline Capital raised their price target to $2. Brookline Capital previously had a hold for Oncternal Therapeutics Inc.
When was the last downgrade for Oncternal Therapeutics (ONCT)?
The last downgrade for Oncternal Therapeutics Inc happened on April 4, 2023 when Maxim Group changed their price target from N/A to N/A for Oncternal Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Oncternal Therapeutics (ONCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncternal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncternal Therapeutics was filed on April 15, 2024 so you should expect the next rating to be made available sometime around April 15, 2025.
Is the Analyst Rating Oncternal Therapeutics (ONCT) correct?
While ratings are subjective and will change, the latest Oncternal Therapeutics (ONCT) rating was a maintained with a price target of $30.00 to $28.00. The current price Oncternal Therapeutics (ONCT) is trading at is $8.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.